Bipolar better than balloon ablation for treating menorrhagia

Article

At 5 years postprocedure, NovaSure, a bipolar radio-frequency impedance-controlled endometrial ablation system, was superior to ThermaChoice, a hot-water balloon ablation technique, at treating menorrhagia, according to the findings of a double-blind, randomized controlled trial conducted in the Netherlands.

At 5 years postprocedure, NovaSure, a bipolar radio-frequency impedance-controlled endometrial ablation system, was superior to ThermaChoice, a hot-water balloon ablation technique, at treating menorrhagia, according to the findings of a double-blind, randomized controlled trial conducted in the Netherlands.

Researchers included 126 premenopausal women with a pictorial blood loss assessment count of 150 or more without intracavitary abnormalities.

They found the response rate 5 years after the fact to be slightly higher in the bipolar group than in the balloon group (96% vs. 90%, respectively).

In addition, significantly more of the bipolar group reported amenorrhea (48% vs. 32%, respectively). Eight women in the bipolar group (9.8%) and five in the balloon group (12.9%) had undergone hysterectomy during the elapsed time. Both groups enjoyed significantly improved quality of life.

Kleijn JH, Engles R, Bourdrez P, et al. Five-year follow up of a randomised controlled trial comparing NovaSure and ThermaChoice endometrial ablation. BJOG. 2008;115:193-198.

Related Videos
Study unveils maternal mortality tracking trends | Image Credit: obhg.com
How Harmonia Healthcare is revolutionizing hyperemesis gravidarum care | Image Credit: hyperemesis.org
Unveiling gender disparities in medicine | Image Credit:  findcare.ahn.org.
Exploring the intersection of heart health and women's health | Image Credit: cedars-sinai.org
Unlocking the benefits of DHEA | Image Credit: drannacabeca.com
Unlocking the power of oxytocin | Image credit: drannacabeca.com
Revolutionizing menopause management: A deep dive into fezolinetant | Image Credit: uvahealth.com.
© 2024 MJH Life Sciences

All rights reserved.